出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年7月
乳房の局在性病変市場：タイプ [ワイヤー、放射性同位元素 (ROLL、RSL)、磁気、電磁位置特定]、用途 (乳房生検、乳房切除術)、エンドユーザー (病院、画像診断センター、外来手術センター) – 2028年までの世界予測
Breast Lesion Localization Market by Type (Wire, Radioisotope (ROLL, RSL), Magnetic, Electromagnetic Localization), Usage (Breast Biopsy, Lumpectomy), End User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers) – Global Forecast to 2028
| ページ数 | 270 |
| 図表数 | 308 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global breast lesion localization market is projected to reach USD 0.4 billion by 2028 from USD 0.3 billion in 2023, at a CAGR of 6.9% during the forecast period. The increasing screening of breast cancer through mammography and the increasing number of improvements in imaging technology have increased the detection of a non-palpable clinically occult breast lesion, which requires perioperative localization.
There have been several technological advancements in breast lesion localization equipment in recent years aimed at improving patient safety, increasing efficiency, and reducing the cost of healthcare.
“Breast biopsy segment accounted for a larger share of the breast lesion localization market”
In 2022, the breast biopsy segment accounted for a larger share of the breast lesion localization market. The large share of this segment can be attributed to the increasing number of patients opting for breast biopsies across the world, the increasing rate of non-palpable breast lesions detected in screening programs, the rising number of breast cancer screening programs, the growing incidence of breast cancer, and an increase in awareness of early cancer detection.
“The electromagnetic localization will grow at highest CAGR during the forecast period”
Based on type, the electromagnetic localization segment is estimated to grow at the highest during the forecast period. The high growth of this segment can be attributed to factors such as reduction in surgical delays, improved patient satisfaction, optimal surgical planning, and no need for radioactive components. A recent development in the field of breast localization methods is the emergence of technologically advanced localization methods, which use electromagnetic waves to localize breast lesions.
“Asia Pacific will grow at highest CAGR during the forecast period”
In 2022, Asia Pacific will grow at highest CAGR during the forecast period. Major factors driving the growth of this market are rising prevalence of breast cancer, increasing healthcare expenditure, and the increasing number of awareness programs for the early detection of breast cancer in several APAC countries. Furthermore, rising government spending on breast cancer research, and growing funding are also driving the market growth in APAC.
The break-up of the profile of primary participants in the breast lesion localization market: Supply-side
• By Company Type: Tier 1 – 55%, Tier 2 – 30%, and Tier 3 – 15%
• By Designation: C Level – 28%, Hospital Director & Managers – 33%, Others-39%
• By Region: North America – 35%, Europe – 20%, Asia Pacific – 30%, Middle East – 9%, and Latin America – 6%
The break-up of the profile of primary participants in the breast lesion localization market: Demand-side
• By End User: Hospitals – 55%, Clinics – 32%, and Ambulatory Surgical Centers – 13%
• By Designation: Doctors – 35%, Hospitals, Directors and Mangers – 27%, Critical Care Specialist-22% Others-16%
• By Region: North America – 17%, Europe – 39%, Asia Pacific – 28%, Middle East – 8%, and Latin America – 8%
The prominent players in the breast lesion localization market include Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US).
Research Coverage:
The report analyzes the breast lesion localization market and aims at estimating the market size and future growth potential of this market based on various segments such as type, usage, end user and region. The report also includes a product portfolio matrix of various breast lesion localization available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall breast lesion localization market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
• Analysis of key drivers (increasing incidence of breast cancer, growing rate of the aging population, increasing awareness on the early detection of breast cancer), restraints (uncertainty in regulatory approval procedures), opportunities (emerging economies offer high growth potential and increasing adoption of technologically advanced localization procedures), and challenges (shortage of oncologists) influencing the growth of the breast lesion localization market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the breast lesion localization market
• Market Development: Comprehensive information on the lucrative emerging markets by type, usage, end user and region.
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global breast lesion localization market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players like Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US) in the global breast lesion localization market.
目次
1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 INCLUSIONS AND EXCLUSIONS 37
1.4 STUDY SCOPE 38
1.4.1 MARKETS COVERED 38
FIGURE 1 MARKET SEGMENTATION 38
1.4.2 YEARS CONSIDERED 38
1.5 CURRENCY CONSIDERED 39
1.6 STAKEHOLDERS 39
1.7 SUMMARY OF CHANGES 39
1.8 RECESSION IMPACT: BREAST LESION LOCALIZATION MARKET 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 2 RESEARCH DESIGN 41
2.1.1 SECONDARY DATA 42
2.1.1.1 Key data from secondary sources 43
2.1.2 PRIMARY DATA 43
FIGURE 3 PRIMARY SOURCES 44
2.1.2.1 Key data from primary sources 45
2.1.2.2 Key industry insights 45
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 46
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 46
2.2 MARKET SIZE ESTIMATION 47
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 48
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: HOLOGIC, INC. 48
FIGURE 8 BREAST LESION LOCALIZATION MARKET: REVENUE SHARE ANALYSIS OF FOUR KEY COMPANIES (2022) 49
FIGURE 9 BREAST LESION LOCALIZATION MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 51
2.2.1 MARKET SEGMENT ASSESSMENT (BY TYPE, USAGE, AND END USER) 52
FIGURE 11 TOP-DOWN APPROACH 52
2.2.2 GEOGRAPHICAL MARKET ASSESSMENT (BY REGION AND COUNTRY) 52
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 53
FIGURE 12 DATA TRIANGULATION METHODOLOGY 53
2.4 STUDY ASSUMPTIONS 54
2.5 RISK ASSESSMENT 54
TABLE 1 BREAST LESION LOCALIZATION MARKET: RISK ASSESSMENT ANALYSIS 54
2.6 RESEARCH LIMITATIONS 55
2.6.1 METHODOLOGY-RELATED LIMITATIONS 55
2.6.2 SCOPE-RELATED LIMITATIONS 55
3 EXECUTIVE SUMMARY 56
FIGURE 13 BREAST LESION LOCALIZATION MARKET, BY TYPE, 2023 VS. 2028 (THOUSAND PROCEDURES) 56
FIGURE 14 BREAST LESION LOCALIZATION MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 57
FIGURE 15 RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2023 VS. 2028 (THOUSAND PROCEDURES) 58
FIGURE 16 RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 58
FIGURE 17 BREAST LESION LOCALIZATION MARKET, BY USAGE, 2023 VS. 2028 (THOUSAND PROCEDURES) 59
FIGURE 18 BREAST LESION LOCALIZATION MARKET, BY USAGE, 2023 VS. 2028 (USD MILLION) 59
FIGURE 19 BREAST LESION LOCALIZATION MARKET, BY END USER, 2023 VS. 2028 (THOUSAND PROCEDURES) 60
FIGURE 20 BREAST LESION LOCALIZATION MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 61
FIGURE 21 GEOGRAPHICAL ANALYSIS: GLOBAL BREAST LESION LOCALIZATION MARKET (PROCEDURES) 62
FIGURE 22 GEOGRAPHICAL ANALYSIS: GLOBAL BREAST LESION LOCALIZATION MARKET (VALUE) 63
4 PREMIUM INSIGHTS 65
4.1 BREAST LESION LOCALIZATION MARKET OVERVIEW 65
FIGURE 23 RISING AWARENESS ABOUT BREAST CANCER AND INCREASING GOVERNMENT INITIATIVES GLOBALLY TO DRIVE MARKET 65
4.2 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY TYPE 66
FIGURE 24 WIRE LOCALIZATION HELD LARGEST SHARE OF ASIA PACIFIC BREAST LESION LOCALIZATION MARKET IN 2022 66
4.3 BREAST LESION LOCALIZATION MARKET (BASED ON VALUE): REGIONAL GROWTH OPPORTUNITIES 67
FIGURE 25 ASIA PACIFIC TO WITNESS HIGHEST GROWTH IN BREAST LESION LOCALIZATION MARKET DURING FORECAST PERIOD 67
4.4 BREAST LESION LOCALIZATION MARKET, BY REGION 68
FIGURE 26 NORTH AMERICA TO DOMINATE BREAST LESION LOCALIZATION MARKET TILL 2028 68
4.5 BREAST LESION LOCALIZATION MARKET: DEVELOPED VS. EMERGING ECONOMIES (USD MILLION) 69
FIGURE 27 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 28 BREAST LESION LOCALIZATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70
5.2.1 DRIVERS 71
5.2.1.1 Increasing incidence of breast cancer 71
TABLE 2 TOP 10 COUNTRIES WITH HIGHEST INCIDENCE OF BREAST CANCER, 2020 71
FIGURE 29 ESTIMATED GLOBAL NUMBER OF NEW BREAST CANCER CASES (2020–2040) 72
5.2.1.2 Growth in aging population 72
5.2.1.3 Increasing awareness on early detection of breast cancer 73
5.2.2 RESTRAINTS 73
5.2.2.1 Uncertainty in regulatory approval procedures 73
5.2.3 OPPORTUNITIES 74
5.2.3.1 High growth potential in emerging economies 74
FIGURE 30 GDP GROWTH FORECAST: COMPARISON AMONG INDIA, CHINA, US, AND GERMANY, 2020 VS. 2040 75
5.2.3.2 Increasing adoption of technologically advanced localization procedures 75
5.2.4 CHALLENGES 76
5.2.4.1 Shortage of oncologists 76
6 INDUSTRY INSIGHTS 77
6.1 INDUSTRY TRENDS 77
6.1.1 ELECTROMAGNETIC WAVES FOR LOCALIZATION OF BREAST LESIONS 77
6.1.2 RADIOFREQUENCY IDENTIFICATION IN BREAST LESION LOCALIZATION 77
6.1.3 MACHINE LEARNING ALGORITHMS FOR COMPUTER-AIDED BREAST LESION DETECTION 78
6.2 IMPACT OF ECONOMIC RECESSION ON BREAST LESION LOCALIZATION MARKET 78
6.3 VALUE CHAIN ANALYSIS 79
FIGURE 31 BREAST LESION LOCALIZATION MARKET: VALUE CHAIN ANALYSIS 80
6.4 REIMBURSEMENT ANALYSIS 80
TABLE 3 MEDICARE REIMBURSEMENT FOR BREAST LESION LOCALIZATION METHODS 81
6.5 TECHNOLOGY ANALYSIS 82
6.5.1 KEY TECHNOLOGIES 83
6.5.1.1 Wire-guided localization (WL) 83
6.5.1.2 Carbon marking 83
6.5.1.3 Radioguided occult lesion localization (ROLL) 83
6.5.1.4 Radioactive seed localization (RSL) 84
6.5.1.5 Magnetic seed localization (MSL) 84
6.5.1.6 Radiofrequency reflector (RFR) 84
6.5.2 COMPLEMENTARY TECHNOLOGIES 84
6.5.2.1 Mammography 84
6.5.2.2 3D mammography or tomosynthesis 85
6.5.2.3 Magnetic resonance imaging 85
6.5.2.4 Ultrasound 85
6.5.3 ADJACENT TECHNOLOGIES 85
6.5.3.1 Computer vision and artificial intelligence 85
6.6 SUPPLY CHAIN ANALYSIS 86
FIGURE 32 BREAST LESION LOCALIZATION MARKET: SUPPLY CHAIN ANALYSIS 87
6.7 ECOSYSTEM MARKET MAPPING 87
FIGURE 33 BREAST LESION LOCALIZATION MARKET: ECOSYSTEM MARKET MAPPING 88
6.8 CASE STUDY ANALYSIS 88
TABLE 4 CASE STUDY 1: ESTIMATING MARKET SIZE OF BREAST LESION LOCALIZATION METHODS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL 88
TABLE 5 CASE STUDY 2: ESTIMATING MARKET SIZE OF BREAST BIOPSY AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL 89
6.9 PORTER’S FIVE FORCES ANALYSIS 89
TABLE 6 BREAST LESION LOCALIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS 89
6.9.1 INTENSITY OF COMPETITIVE RIVALRY 89
6.9.2 BARGAINING POWER OF SUPPLIERS 90
6.9.3 BARGAINING POWER OF BUYERS 90
6.9.4 THREAT OF SUBSTITUTES 90
6.9.5 THREAT OF NEW ENTRANTS 90
6.10 REGULATORY ANALYSIS 91
6.10.1 NORTH AMERICA 91
6.10.1.1 US 91
TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION 91
TABLE 8 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 91
6.10.1.2 Canada 92
TABLE 9 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 92
TABLE 10 CLASSIFICATION OF BREAST LESION LOCALIZATION DEVICES ACCORDING TO GOVERNMENT OF CANADA 92
6.10.2 EUROPE 92
FIGURE 34 EUROPE: CLASS III MEDICAL DEVICES 93
6.10.3 ASIA PACIFIC 93
6.10.3.1 India 93
6.11 PATENT ANALYSIS 94
6.11.1 PATENT PUBLICATION TRENDS FOR BREAST LESIONS 94
FIGURE 35 PATENT PUBLICATION TRENDS (JANUARY 2013–MAY 2023) 94
6.11.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 95
FIGURE 36 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR BREAST LESION PATENTS (JANUARY 2013–MAY 2023) 95
FIGURE 37 TOP APPLICANT COUNTRIES/REGIONS FOR BREAST LESION PATENTS (JANUARY 2013–MAY 2023) 96
6.12 INDICATIVE PRICING MODEL ANALYSIS 96
TABLE 11 AVERAGE SELLING PRICE OF BREAST LESION LOCALIZATION CONSUMABLES (2023) 97
6.12.1 AVERAGE SELLING PRICE TRENDS 97
6.13 KEY CONFERENCES AND EVENTS IN 2023–2024 98
6.14 KEY STAKEHOLDERS AND BUYING CRITERIA 99
6.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 99
FIGURE 38 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BREAST LESION LOCALIZATION TYPE 99
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BREAST LESION LOCALIZATION TYPE 99
6.14.2 BUYING CRITERIA 100
FIGURE 39 KEY BUYING CRITERIA FOR BREAST LESION LOCALIZATION 100
TABLE 13 KEY BUYING CRITERIA FOR BREAST LESION LOCALIZATION 100
7 BREAST LESION LOCALIZATION MARKET, BY TYPE 101
7.1 INTRODUCTION 102
TABLE 14 BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 102
TABLE 15 BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 102
7.2 WIRE LOCALIZATION 103
7.2.1 WIRE LOCALIZATION SEGMENT TO COMMAND LARGEST SHARE OF BREAST LESION LOCALIZATION MARKET 103
TABLE 16 WIRE LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 104
TABLE 17 WIRE LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
7.3 RADIOISOTOPE LOCALIZATION 105
TABLE 18 RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 106
TABLE 19 RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 106
TABLE 20 RADIOISOTOPE LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 107
TABLE 21 RADIOISOTOPE LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
7.3.1 RADIOGUIDED OCCULT LESION LOCALIZATION 108
7.3.1.1 Radioguided occult lesion localization to result in shorter operating times and higher rates of tumor-free margins 108
TABLE 22 RADIOGUIDED OCCULT LESION LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 109
TABLE 23 RADIOGUIDED OCCULT LESION LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
7.3.2 RADIOACTIVE SEED LOCALIZATION 110
7.3.2.1 Decreased operative time and long half-life of radioactive seed localization to drive segment 110
TABLE 24 RADIOACTIVE SEED LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 111
TABLE 25 RADIOACTIVE SEED LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
7.4 MAGNETIC LOCALIZATION 112
7.4.1 INCREASED WORKFLOW EFFICIENCY AND COST-EFFECTIVENESS TO DRIVE MARKET 112
TABLE 26 MAGNETIC LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 113
TABLE 27 MAGNETIC LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
7.5 ELECTROMAGNETIC LOCALIZATION 114
7.5.1 ELECTROMAGNETIC LOCALIZATION TO ENABLE SMALLER INCISIONS DURING SURGERIES 114
TABLE 28 ELECTROMAGNETIC LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 115
TABLE 29 ELECTROMAGNETIC LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
7.6 OTHER LOCALIZATION TYPES 116
TABLE 30 OTHER LOCALIZATION TYPES MARKET, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 117
TABLE 31 OTHER LOCALIZATION TYPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
8 BREAST LESION LOCALIZATION MARKET, BY USAGE 119
8.1 INTRODUCTION 120
TABLE 32 BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 120
TABLE 33 BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 121
8.2 BREAST BIOPSY 121
8.2.1 GROWING INCIDENCE OF BREAST CANCER TO DRIVE MARKET 121
TABLE 34 BREAST LESION LOCALIZATION MARKET FOR BREAST BIOPSY, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 122
TABLE 35 BREAST LESION LOCALIZATION MARKET FOR BREAST BIOPSY, BY COUNTRY, 2021–2028 (USD MILLION) 123
8.3 BREAST CONSERVATION (LUMPECTOMY) 123
8.3.1 INCREASING ADOPTION OF BREAST CONSERVATION PROCEDURES TO DRIVE MARKET 123
TABLE 36 BREAST LESION LOCALIZATION MARKET FOR BREAST CONSERVATION, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 124
TABLE 37 BREAST LESION LOCALIZATION MARKET FOR BREAST CONSERVATION, BY COUNTRY, 2021–2028 (USD MILLION) 125
9 BREAST LESION LOCALIZATION MARKET, BY END USER 126
9.1 INTRODUCTION 127
TABLE 38 BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 127
TABLE 39 BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 127
9.2 HOSPITALS AND CLINICS 128
9.2.1 HOSPITALS TO PERFORM LARGE NUMBER OF BREAST LESION LOCALIZATION PROCEDURES 128
TABLE 40 BREAST LESION LOCALIZATION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 129
TABLE 41 BREAST LESION LOCALIZATION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 130
9.3 DIAGNOSTIC IMAGING CENTERS 130
9.3.1 INCREASED DEMAND FOR EARLY DIAGNOSIS TO DRIVE MARKET 130
TABLE 42 BREAST LESION LOCALIZATION MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 131
TABLE 43 BREAST LESION LOCALIZATION MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 132
9.4 AMBULATORY SURGICAL CENTERS 132
9.4.1 INCREASING NUMBER OF OUTPATIENT VISITS TO DRIVE MARKET 132
TABLE 44 BREAST LESION LOCALIZATION MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 133
TABLE 45 BREAST LESION LOCALIZATION MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 134
9.5 OTHER END USERS 134
TABLE 46 BREAST LESION LOCALIZATION MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 135
TABLE 47 BREAST LESION LOCALIZATION MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 136
10 BREAST LESION LOCALIZATION MARKET, BY REGION 137
10.1 INTRODUCTION 138
FIGURE 40 NUMBER OF BREAST CANCER CASES VS. NUMBER OF DEATHS IN 2020 (THOUSANDS) 138
FIGURE 41 BREAST LESION LOCALIZATION MARKET: GEOGRAPHICAL SNAPSHOT 139
TABLE 48 BREAST LESION LOCALIZATION MARKET, BY REGION, 2021–2028 (THOUSAND PROCEDURES) 139
TABLE 49 BREAST LESION LOCALIZATION MARKET, BY REGION, 2021–2028 (USD MILLION) 140
10.2 NORTH AMERICA 140
FIGURE 42 NORTH AMERICA: NUMBER OF BREAST CANCER CASES IN 2020 (THOUSANDS) 140
10.2.1 NORTH AMERICA: RECESSION IMPACT 141
TABLE 50 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 142
TABLE 51 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 52 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 142
TABLE 53 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 54 NORTH AMERICA: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 143
TABLE 55 NORTH AMERICA: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 56 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 144
TABLE 57 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 144
TABLE 58 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 145
TABLE 59 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 145
10.2.2 US 145
10.2.2.1 High adoption of innovative technologies to drive market 145
TABLE 60 US: KEY MACROINDICATORS 146
TABLE 61 US: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 146
TABLE 62 US: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 63 US: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 147
TABLE 64 US: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 65 US: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 148
TABLE 66 US: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 148
TABLE 67 US: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 148
TABLE 68 US: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 149
10.2.3 CANADA 149
10.2.3.1 Supportive government initiatives for breast cancer awareness to drive market 149
TABLE 69 CANADA: KEY MACROINDICATORS 150
TABLE 70 CANADA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 150
TABLE 71 CANADA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 72 CANADA: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 151
TABLE 73 CANADA: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 74 CANADA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 152
TABLE 75 CANADA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 152
TABLE 76 CANADA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 152
TABLE 77 CANADA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 153
10.3 EUROPE 153
FIGURE 44 EUROPE: NUMBER OF BREAST CANCER CASES IN 2020 (THOUSANDS) 154
10.3.1 EUROPE: RECESSION IMPACT 154
TABLE 78 EUROPE: BREAST LESION LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 156
TABLE 79 EUROPE: BREAST LESION LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 80 EUROPE: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 157
TABLE 81 EUROPE: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 82 EUROPE: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 158
TABLE 83 EUROPE: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 84 EUROPE: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 158
TABLE 85 EUROPE: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 159
TABLE 86 EUROPE: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 159
TABLE 87 EUROPE: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 160
10.3.2 GERMANY 160
10.3.2.1 Favorable reimbursement policies for healthcare procedures to drive market 160
TABLE 88 GERMANY: KEY MACROINDICATORS 161
TABLE 89 GERMANY: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 161
TABLE 90 GERMANY: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 91 GERMANY: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 162
TABLE 92 GERMANY: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 93 GERMANY: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 163
TABLE 94 GERMANY: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 163
TABLE 95 GERMANY: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 163
TABLE 96 GERMANY: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 164
10.3.3 FRANCE 164
10.3.3.1 Rising incidences of breast cancer among aged women to drive market 164
TABLE 97 FRANCE: KEY MACROINDICATORS 165
TABLE 98 FRANCE: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 165
TABLE 99 FRANCE: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 100 FRANCE: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 166
TABLE 101 FRANCE: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 102 FRANCE: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 167
TABLE 103 FRANCE: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 167
TABLE 104 FRANCE: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 167
TABLE 105 FRANCE: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 168
10.3.4 UK 168
10.3.4.1 Increasing public-private initiatives for breast cancer awareness to drive market 168
TABLE 106 UK: KEY MACROINDICATORS 169
TABLE 107 UK: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 169
TABLE 108 UK: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 109 UK: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 170
TABLE 110 UK: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 111 UK: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 171
TABLE 112 UK: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 171
TABLE 113 UK: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 171
TABLE 114 UK: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 172
10.3.5 ITALY 172
10.3.5.1 Increasing demand for breast lesion localization systems to drive market 172
TABLE 115 ITALY: KEY MACROINDICATORS 173
TABLE 116 ITALY: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 173
TABLE 117 ITALY: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 174
TABLE 118 ITALY: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 174
TABLE 119 ITALY: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 174
TABLE 120 ITALY: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 175
TABLE 121 ITALY: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 175
TABLE 122 ITALY: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 175
TABLE 123 ITALY: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 176
10.3.6 SPAIN 176
10.3.6.1 Growing access to advanced cancer screening programs to drive market 176
TABLE 124 SPAIN: KEY MACROINDICATORS 177
TABLE 125 SPAIN: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 177
TABLE 126 SPAIN: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 127 SPAIN: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 178
TABLE 128 SPAIN: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 129 SPAIN: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 179
TABLE 130 SPAIN: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 179
TABLE 131 SPAIN: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 179
TABLE 132 SPAIN: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 180
10.3.7 REST OF EUROPE 180
TABLE 133 REST OF EUROPE: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 180
TABLE 134 REST OF EUROPE: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 135 REST OF EUROPE: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 181
TABLE 136 REST OF EUROPE: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 137 REST OF EUROPE: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 182
TABLE 138 REST OF EUROPE: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 182
TABLE 139 REST OF EUROPE: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 183
TABLE 140 REST OF EUROPE: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 183
10.4 ASIA PACIFIC 184
FIGURE 46 ASIA PACIFIC: NUMBER OF BREAST CANCER CASES, 2020 (IN THOUSANDS) 184
10.4.1 ASIA PACIFIC: RECESSION IMPACT 184
TABLE 141 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (THOUSAND PROCEDURES) 186
TABLE 142 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 143 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 187
TABLE 144 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 145 ASIA PACIFIC: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 188
TABLE 146 ASIA PACIFIC: RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 147 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 188
TABLE 148 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 189
TABLE 149 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 189
TABLE 150 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 190
10.4.2 CHINA 190
10.4.2.1 Increasing patient pool and developing government healthcare initiatives to drive market 190
TABLE 151 CHINA: KEY MACROINDICATORS 191
TABLE 152 CHINA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 191
TABLE 153 CHINA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 154 CHINA: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 192
TABLE 155 CHINA: RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 156 CHINA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 193
TABLE 157 CHINA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 193
TABLE 158 CHINA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 194
TABLE 159 CHINA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 194
10.4.3 JAPAN 195
10.4.3.1 Increasing number of universal healthcare reimbursement policies to drive market 195
TABLE 160 JAPAN: KEY MACROINDICATORS 195
TABLE 161 JAPAN: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 196
TABLE 162 JAPAN: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 163 JAPAN: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 197
TABLE 164 JAPAN: RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 165 JAPAN: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 197
TABLE 166 JAPAN: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 198
TABLE 167 JAPAN: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 198
TABLE 168 JAPAN: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 199
10.4.4 INDIA 199
10.4.4.1 Increasing government Initiatives for female health improvement to drive market 199
TABLE 169 INDIA: KEY MACROINDICATORS 200
TABLE 170 INDIA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 200
TABLE 171 INDIA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 172 INDIA: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 201
TABLE 173 INDIA: RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 174 INDIA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 202
TABLE 175 INDIA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 202
TABLE 176 INDIA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 203
TABLE 177 INDIA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 203
10.4.5 AUSTRALIA 203
10.4.5.1 Growing breast cancer awareness campaigns by public and private organizations to drive market 203
TABLE 178 AUSTRALIA: KEY MACROINDICATORS 204
TABLE 179 AUSTRALIA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 204
TABLE 180 AUSTRALIA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 181 AUSTRALIA: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 205
TABLE 182 AUSTRALIA: RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 183 AUSTRALIA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 206
TABLE 184 AUSTRALIA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 206
TABLE 185 AUSTRALIA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 207
TABLE 186 AUSTRALIA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 207
10.4.6 SOUTH KOREA 207
10.4.6.1 Growing government awareness campaigns and rising incidences of breast cancer to drive market 207
TABLE 187 SOUTH KOREA: KEY MACROINDICATORS 208
TABLE 188 SOUTH KOREA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 208
TABLE 189 SOUTH KOREA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 209
TABLE 190 SOUTH KOREA: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 209
TABLE 191 SOUTH KOREA: RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 192 SOUTH KOREA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 210
TABLE 193 SOUTH KOREA: BREAST LESION LOCALIZATION PRODUCTS MARKET, BY USAGE, 2021–2028 (USD MILLION) 210
TABLE 194 SOUTH KOREA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 211
TABLE 195 SOUTH KOREA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 211
10.4.7 REST OF ASIA PACIFIC 211
TABLE 196 REST OF ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 212
TABLE 197 REST OF ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 198 REST OF ASIA PACIFIC: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 213
TABLE 199 REST OF ASIA PACIFIC: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 200 REST OF ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 213
TABLE 201 REST OF ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 214
TABLE 202 REST OF ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 214
TABLE 203 REST OF ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 215
10.5 LATIN AMERICA 215
10.5.1 RISING GERIATRIC POPULATION AND PRESENCE OF FAVORABLE REGULATORY ENVIRONMENT TO DRIVE MARKET 215
10.5.2 LATIN AMERICA: RECESSION IMPACT 216
TABLE 204 LATIN AMERICA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 216
TABLE 205 LATIN AMERICA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 206 LATIN AMERICA: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 217
TABLE 207 LATIN AMERICA: RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 208 LATIN AMERICA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 218
TABLE 209 LATIN AMERICA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 218
TABLE 210 LATIN AMERICA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 219
TABLE 211 LATIN AMERICA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 219
10.6 MIDDLE EAST & AFRICA 220
10.6.1 RISING GOVERNMENT INVESTMENTS AND INCREASING BREAST CANCER AWARENESS PROGRAMS TO DRIVE MARKET 220
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 220
TABLE 212 MIDDLE EAST & AFRICA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 221
TABLE 213 MIDDLE EAST & AFRICA: BREAST LESION LOCALIZATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 214 MIDDLE EAST & AFRICA: RADIOISOTOPE LOCALIZATION MARKET, BY TYPE, 2021–2028 (THOUSAND PROCEDURES) 222
TABLE 215 MIDDLE EAST & AFRICA: RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 216 MIDDLE EAST & AFRICA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (THOUSAND PROCEDURES) 222
TABLE 217 MIDDLE EAST & AFRICA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2021–2028 (USD MILLION) 223
TABLE 218 MIDDLE EAST & AFRICA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (THOUSAND PROCEDURES) 223
TABLE 219 MIDDLE EAST & AFRICA: BREAST LESION LOCALIZATION MARKET, BY END USER, 2021–2028 (USD MILLION) 224″ “11 COMPETITIVE LANDSCAPE 225
11.1 INTRODUCTION 225
FIGURE 48 KEY DEVELOPMENTS IN BREAST LESION LOCALIZATION MARKET 225
11.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 226
FIGURE 49 BREAST LESION LOCALIZATION MARKET: REVENUE ANALYSIS OF KEY PLAYERS (2018–2022) 226
11.3 MARKET SHARE ANALYSIS 226
FIGURE 50 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 227
11.4 COMPANY EVALUATION MATRIX 228
11.4.1 STARS 228
11.4.2 EMERGING LEADERS 228
11.4.3 PERVASIVE PLAYERS 228
11.4.4 PARTICIPANTS 228
FIGURE 51 BREAST LESION LOCALIZATION MARKET: COMPANY EVALUATION MATRIX, 2022 229
11.5 COMPANY EVALUATION MATRIX FOR START-UPS 230
11.5.1 PROGRESSIVE COMPANIES 230
11.5.2 DYNAMIC COMPANIES 230
11.5.3 STARTING BLOCKS 230
11.5.4 RESPONSIVE COMPANIES 230
FIGURE 52 BREAST LESION LOCALIZATION MARKET: COMPANY EVALUATION MATRIX FOR START-UPS (2022) 231
11.6 COMPANY PRODUCT FOOTPRINT 232
TABLE 220 BREAST LESION LOCALIZATION MARKET: PRODUCT PORTFOLIO ANALYSIS 232
11.7 REGIONAL FOOTPRINT OF MAJOR PLAYERS IN BREAST LESION LOCALIZATION MARKET 233
TABLE 221 BREAST LESION LOCALIZATION MARKET: GEOGRAPHICAL REVENUE MIX 233
11.8 COMPETITIVE BENCHMARKING 234
TABLE 222 BREAST LESION LOCALIZATION MARKET: KEY START-UPS 234
11.9 COMPETITIVE SITUATIONS AND TRENDS 235
11.9.1 KEY PRODUCT LAUNCHES 235
TABLE 223 BREAST LESION LOCALIZATION MARKET: KEY PRODUCT LAUNCHES (2020–2023) 235
11.9.2 KEY DEALS 235
TABLE 224 KEY DEALS (2020–2021) 235
11.10 BREAST LESION LOCALIZATION METHODS: COMPARATIVE ANALYSIS 236
11.11 BREAST LESION LOCALIZATION METHODS: COMPARATIVE ANALYSIS 237
FIGURE 53 COMPARATIVE ANALYSIS: DETECTION RATE, SUCCESS RATE, AND RE-EXCISION RATE 237
11.12 BREAST LESION LOCALIZATION METHODS: SELECTION CRITERIA EVALUATION 238
FIGURE 54 SELECTION CRITERIA EVALUATION 238
11.13 QUALITATIVE ASSESSMENT OF REPLACEMENT TRENDS 239
FIGURE 55 REPLACEMENT TRENDS 239
12 COMPANY PROFILES 240
12.1 KEY PLAYERS 240
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 HOLOGIC, INC. 240
TABLE 225 HOLOGIC, INC.: COMPANY OVERVIEW 240
FIGURE 56 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 241
12.1.2 BECTON, DICKINSON AND COMPANY 244
TABLE 226 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 244
FIGURE 57 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 245
12.1.3 MERIT MEDICAL SYSTEMS 247
TABLE 227 MERIT MEDICAL SYSTEMS: COMPANY OVERVIEW 247
FIGURE 58 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022) 248
12.1.4 LEICA BIOSYSTEMS NUSSLOCH GMBH 250
TABLE 228 DANAHER: COMPANY OVERVIEW 250
FIGURE 59 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 251
12.1.5 ARGON MEDICAL DEVICES 253
TABLE 229 ARGON MEDICAL DEVICES: COMPANY OVERVIEW 253
12.1.6 LAURANE MEDICAL LLC 255
TABLE 230 LAURANE MEDICAL LLC: COMPANY OVERVIEW 255
12.1.7 ENDOMAGNETICS LTD. (ENDOMAG) 256
TABLE 231 ENDOMAGNETICS LIMITED: COMPANY OVERVIEW 256
12.1.8 INTRAMEDICAL IMAGING, LLC 257
TABLE 232 INTRAMEDICAL IMAGING, LLC: COMPANY OVERVIEW 257
12.1.9 ISOAID 258
TABLE 233 ISOAID: COMPANY OVERVIEW 258
12.1.10 SURGICEYE GMBH 259
TABLE 234 SURGICEYE GMBH: COMPANY OVERVIEW 259
12.2 OTHER PLAYERS 260
12.2.1 RANFAC CORP. 260
TABLE 235 RANFAC CORP.: COMPANY OVERVIEW 260
12.2.2 MERMAID MEDICAL GROUP 261
TABLE 236 MERMAID MEDICAL GROUP: COMPANY OVERVIEW 261
12.2.3 IZI MEDICAL PRODUCTS, LLC 262
TABLE 237 IZI MEDICAL PRODUCTS, LLC: COMPANY OVERVIEW 262
12.2.4 MATEK MEDIKAL 263
TABLE 238 MATEK MEDIKAL: COMPANY OVERVIEW 263
12.2.5 TSUNAMI MEDICAL SRL 264
TABLE 239 TSUNAMI MEDICAL SRL: COMPANY OVERVIEW 264
12.2.6 BPB MEDICA 265
TABLE 240 BPB MEDICA: COMPANY OVERVIEW 265
12.2.7 SIRIUS MEDICAL SYSTEMS B.V. 266
TABLE 241 SIRIUS MEDICAL SYSTEMS B.V.: COMPANY OVERVIEW 266
12.2.8 MOLLI SURGICAL INC. 267
TABLE 242 MOLLI SURGICAL INC.: COMPANY OVERVIEW 267
12.2.9 STERYLAB S.R.L. 268
TABLE 243 STERYLAB S.R.L.: COMPANY OVERVIEW 268
12.2.10 CP MEDICAL 269
TABLE 244 CP MEDICAL: COMPANY OVERVIEW 269
12.2.11 MDL SRL 270
TABLE 245 MDL SRL: COMPANY OVERVIEW 270
12.2.12 BIOMEDICAL SRL 271
TABLE 246 BIOMEDICAL SRL: COMPANY OVERVIEW 271
12.2.13 ELUCENT MEDICAL 272
TABLE 247 ELUCENT MEDICAL: COMPANY OVERVIEW 272
12.2.14 VIGEO SRL 273
TABLE 248 VIGEO SRL: COMPANY OVERVIEW 273
12.2.15 MEDAX MEDICAL DEVICES 274
TABLE 249 MEDAX MEDICAL DEVICES: COMPANY OVERVIEW 274
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX 275
13.1 DISCUSSION GUIDE 275
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 278
13.3 RELATED REPORTS 280
13.4 AUTHOR DETAILS 281